Featured
| Dec 19 | Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities read more » |
| Dec 17 | Phase 1/2 trial data may support AMT-130 approval, FDA says read more » |
| Dec 16 | Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer read more » |
| Dec 18 | Proof-of-concept study bioengineers therapeutics for improved cancer treatment read more » |
| Dec 18 | Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform read more » |
| Dec 13 | Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone read more » |
| Dec 13 | Light-Induced Gene Therapy Disables Cancer Cells' Mitochondria in Mice read more » |
| Dec 13 | Signal Peptide Harnesses Exosomes for Precise Drug Delivery read more » |
| Dec 11 | Genes That Determine Tooth Shape Identified, Including One Inherited from the Neanderthals read more » |
| Dec 11 | Chroma Medicine, Nvelop Therapeutics Merge as nChroma Bio with Focus on Epigenetic Therapies read more » |
| Dec 24 | Metabolic reprogramming, sensing, and cancer therapy read more » |
| Dec 24 | Early host defense against virus infections read more » |
| Dec 24 | Pancreatic β cell interleukin-22 receptor subunit alpha 1 deficiency impairs β cell function in type 2 diabetes via cytochrome b5 reductase 3 read more » |
| Dec 24 | Activation-derepression synergy enables a bHLH network to coordinate a signal-specific fate response read more » |
| Dec 18 | Myelodysplasia after Lentiviral Gene Therapy read more » |
| Dec 18 | AAV library screening identifies novel vector for efficient transduction of human aorta read more » |
| Dec 16 | Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 high-pathogenicity avian influenza virus with reduced adverse reactions read more » |
| Dec 13 | Preclinical development of lentiviral vector gene therapy for Diamond-Blackfan anemia syndrome read more » |
| Dec 13 | In vivo evolution of env in SHIV-AD8EO-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig read more » |
| Dec 13 | Tailoring capsid directed evolution technology for improved AAV-mediated CAR-T generation read more » |
PackGene’s Newsletter
Receive the latest news and insights to your inbox.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo and Astellas Collaborate to Advance Neurological Gene Therapies Using AAV Capsid Technology
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, and Astellas Pharma Inc. (TSE: 4503), a global innovator in life sciences, have partnered under a new license agreement. This collaboration centers around Sangamo’s cutting-edge neurotropic AAV...
Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform
SHANGHAI and MORRISVILLE, N.C., Dec. 18, 2024 /PRNewswire/ -- Inceptor Bio, a leading innovator in cell therapy, and GRIT Bio, a clinical-stage immunotherapy developer, today announced a strategic partnership to advance IB-T101, a potentially best-in-class CAR-T...
Proof-of-concept study bioengineers therapeutics for improved cancer treatment
Credit: Pixabay/CC0 Public DomainA team of Children's Medical Research Institute (CMRI) scientists has identified a new method for producing a therapeutic product that has the potential to improve the treatment of cancer. The work by Associate Professor Leszek...
FDA Agrees to Accelerated Approval Pathway for Promising Huntington’s Disease Gene Therapy
The U.S. Food and Drug Administration (FDA) has agreed that data from two ongoing Phase 1/2 clinical trials, compared with an external control group of untreated patients, may suffice to support an accelerated approval application for a groundbreaking gene therapy for...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
